Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials

Abstract

Introduction Adults with atopic dermatitis (AD) commonly report adult-onset disease. AD is associated with different genetics, lesion morphology and distribution, and symptoms by age of onset. Yet little is known about possible differences in treatment efficacy between adults with adult-onset or childhood-onset AD. Methods We evaluated the efficacy of dupilumab by age of AD onset in adults with moderate-to-severe AD, using pooled data from the LIBERTY AD SOLO 1 and 2 studies (NCT02277743, NCT02277769). Results were stratified based on self-reported age of AD onset, divided into four age subgroups: 0–4, 5–9, 10–19, and over 20 years. Results This analysis included 460 patients treated with placebo and 457 treated with dupilumab 300 mg every 2 weeks (q2w), with a mean patient age of 38 years. Most patients (53.2%) reported AD onset at 0–4 years, with 14% at 5–9 years, 13.4% at 10–19 years, and 18.5% at 20 years or older. Dupilumab significantly improved AD signs and symptoms over 16 weeks compared with placebo, regardless of age of onset. Dupilumab treatment resulted in a significantly greater proportion of patients achieving Eczema Area and Severity Index (EASI)-50, EASI-75, and EASI-90 (50%, 75%, and 90% improvement from baseline EASI, respectively), and clear or almost clear skin (Investigator’s Global Assessment score 0 or 1) across all age-of-onset subgroups compared with placebo. In addition, EASI improvements were significant across all anatomical regions in all subgroups. Weekly average peak pruritus Numerical Rating Scale and Dermatology Life Quality Index also improved consistently and significantly with dupilumab versus placebo, regardless of age of onset. Conclusion Despite possible differences in presentation and progression of AD linked to age of onset, dupilumab showed similar significant and sustained improvements in AD signs, symptoms, and quality of life in adults compared with placebo, over 16 weeks of treatment. Trial Registration LIBERTY AD SOLO 1: NCT02277743; LIBERTY AD SOLO 2: NCT02277769. Infographic available for this article.

Dupilumab in the treatment of severe adopic dermatitis and respiratory allergy: a case report

“…Препараты моноклональных антител как вариант таргетной терапии все чаще применяются в терапии иммунопатологических состояний. Так, дупилумаб стал одним из наиболее успешных препаратов, направленных на блокаду активации IL-4R через IL-4 и IL-13 [1,[10][11][12][13]. Дупилумаб, зарегистрированный в 2017 г. FDA и EMA, является рекомбинантным моноклональным человеческим антителом класса IgG4, которое связывает IL-4Ra.…”

Extracts of Grifola frondosa inhibit the MAPK signaling pathways involved in keratinocyte inflammation and ameliorate atopic dermatitis

“…At present, treatments that block IL-4 and IL-13, including the IL-4Rα blocker dupilumab and the anti-IL-13 drug tralokinumab, have shown positive results in individuals with AD [ 3 ]. However, the efficacy of these therapeutic approaches in fully mitigating all symptoms of the condition and whether they will sustain long-term benefits remain unclear [ 1 ].…”

Did dupilumab unmask smoldering mycosis fungoides?

“…Dupilumab, a monoclonal antibody targeting the interleukin 4 receptor α subunit, is now routinely prescribed for moderate-to-severe adult-onset eczema. 2 The presentation of CTCLs and mycosis fungoides (MF) after dupilumab initiation has been reported in recent literature. 3 , 4 This potentially fatal adverse outcome requires additional attention because the relationship between CTCLs and dupilumab use is not well understood.…”